NEW YORK, Feb. 29, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a...
Management to host conference call on Thursday, March 7, 2024, at 8:30 a.m. ET FLORHAM PARK, N.J., Feb. 29, 2024...
First patients in clinical study at Beilinson Hospital were scanned with the Nanox.ARC, a stationary X-ray system that produces 3D...
— Record revenues of $675 million in 2023 — — Full-year GAAP net income of $42 million and adjusted EBITDA...
MINNEAPOLIS, MN, US, Feb. 29, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the “Company” or “PetVivo")...
SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano’s...
Long-term CNM-Au8 treatment demonstrated significant and clinically meaningful improvement of vision as measured by low contrast letter acuity (LCLA), an...
SAN MATEO, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing...
Preclinical Research on Full-Thickness Cutaneous Wound Healing KNOXVILLE, TN, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or...
REVEAL adolescent and adult trial will proceed to high dose cohort following Independent Data Monitoring Committee approval of Company’s request...
SOLANA BEACH, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell,...
$60 million financing upfront with up to an additional $64.2 million tied to exercise of milestone-driven warrants Upfront net proceeds...
Investor webcast on Monday, March 4 at 8:00 a.m. ET to present clinical dataSOUTH SAN FRANCISCO, Calif., Feb. 29, 2024...
2023 was a transformative year for VYNE, marked by the achievement of clinical proof-of-concept for VYN201 in vitiligo and a successful...
SYDNEY, Australia, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (the Company), the Company developing...
BOSTON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based...
Conference Call to be held the same day at 9:00am Eastern TimeATLANTA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences,...
~ Partnership Will Significantly Expand Depth and Diversity of Real World Data Availability for Life Science Innovation ~MINNEAPOLIS, Feb. 29,...
Accelerated pace of enrollment supports speed to market strategy Topline results from Stage 1 expected to be presented in the...
Additional data from recently reported positive Phase 3 RESILIENT trial will be presentedCHATHAM, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) --...